Orphan drugs in Europe

被引:0
|
作者
Emma Dorey
机构
关键词
D O I
10.1038/11639
中图分类号
学科分类号
摘要
引用
收藏
页码:737 / 737
相关论文
共 50 条
  • [41] COMPARISON OF THE TRENDS OF ORPHAN DRUGS DESIGNATIONS AND APPROVALS IN THE UNITED STATES AND EUROPE IN ONCOLOGY
    Hanna, E.
    Korchagina, D.
    Toumi, M.
    VALUE IN HEALTH, 2016, 19 (07) : A892 - A892
  • [42] Involvement of Patient Organisations in Research and Development of Orphan Drugs for Rare Diseases in Europe
    Mavris, M.
    Le Cam, Y.
    MOLECULAR SYNDROMOLOGY, 2012, 3 (05) : 237 - 243
  • [43] Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases
    Micallef, Joelle
    Blin, Olivier
    THERAPIE, 2020, 75 (02): : 133 - 139
  • [44] IS THE ORPHANAGE FILLING UP? PROJECTING THE GROWTH AND BUDGET IMPACT OF ORPHAN DRUGS IN EUROPE
    Flostrand, S.
    Rodriguez, I
    Maddox, B.
    Finch, L.
    Belulaj, S.
    Gould, A.
    VALUE IN HEALTH, 2016, 19 (07) : A599 - A599
  • [45] Development of Orphan Drugs in Japan: Characteristics of Orphan Drugs Developed in Japan
    Makoto Shiragami
    Kiyohito Nakai
    Drug information journal : DIJ / Drug Information Association, 2000, 34 (3): : 839 - 846
  • [46] Development of orphan drugs in Japan: Characteristics of orphan drugs developed in Japan
    Shiragami, M
    Nakai, K
    DRUG INFORMATION JOURNAL, 2000, 34 (03): : 839 - 846
  • [47] A COMPARATIVE STUDY OF ACCESS TO ORPHAN DRUGS AND ORPHAN DRUGS REGULATIONS AND POLICIES
    Ounsirithupsakul, T.
    Samphansompoch, T.
    Sermsakulthai, T.
    Taychakhoonavudh, S.
    VALUE IN HEALTH, 2018, 21 : S49 - S49
  • [48] ORPHAN DISEASES AND ORPHAN DRUGS - SCHEINBERG, WALSHE
    QURESHI, B
    JOURNAL OF THE ROYAL SOCIETY OF HEALTH, 1987, 107 (04): : 160 - 160
  • [49] Orphan drugs for myelofibrosis
    Harrison, Claire N.
    Bennett, Michael
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (04): : 391 - 405
  • [50] The problem of orphan drugs
    Ferner, Robin E.
    Hughes, Dyfrig A.
    BRITISH MEDICAL JOURNAL, 2010, 341